Por: ABC News Health September 26, 2023
TOKYO -- Japan's health ministry has approved Leqembi, a drug for Alzheimer’s disease that was jointly developed by ese and U.S. pharmaceutical companies. It's the first drug for treatment of the disease in a country with a rapidly aging population.Developed by Japanese drugmaker Eisai Co. and U.S. biotechnology firm Biogen Inc., the drug's approval in Japan comes two months after it was endorsed by the U.S. Food and Drug... + full article
ABC7 USA Health July 07, 2023
WASHINGTON -- U.S. officials granted full approval to a closely watched Alzheimer's drug on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease.The Food and Drug Administration endorsed... + más
Reimagining Alzheimer’s (Part 4): Cautious Optimism For A New Alzheimer’s Disease Treatment | Forbes
Alzheimer's drug trial shown to slow cognitive decline in long fight against dementia | CNBC
ABC News USA Health July 07, 2023
In a positive step forward for Alzheimer's disease treatment, the Food and Drug Administration on Thursday evening granted full approval for a new drug called .Leqembi is the first drug of its kind with clear evidence it can slow cognitive decline in people with early... + más
What Are the Duties of A Trustee? | Forbes
NBA playoffs 2023: Our insiders dissect the Eastern and Western conference finals | ABC7
CNBC USA Health March 14, 2023
In this articleThe Alzheimer's drug Leqembi is seen in this undated handout image obtained by Reuters on January 20, 2023.Eisai via ReutersThe Veterans Health Administration will cover and 's Alzheimer's treatment Leqembi, the companies announced Monday.In a... + más
Medicare rejects Alzheimer's Association request for unrestricted coverage of treatments like Leqembi | CNBC
Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage | CNBC
CNBC USA Health February 24, 2023
The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023.Eisai via ReutersMedicare will not provide broader coverage of the Alzheimer's drug Leqembi until it receives more evidence that the treatment is reasonable and... + más
Why a new Alzheimer's drug is having a slow US debut | ABC News
CNBC USA Health February 17, 2023
In this articleTek Image/science Photo Library Science Photo Library Getty ImagesJapanese drugmaker expects the Food and Drug Administration to fully approve its Alzheimer's treatment Leqembi this summer, which would expand access to the pricey new antibody under... + más
A new Alzheimer’s drug has been approved. What to know about lecanemab | Orlando Sentinel
Forbes USA Business October 15, 2022
Getty Images Key Takeaways You may have heard the overwhelmingly positive news for Biogen lately—this stock has been a rare winner during a time of extreme volatility in the stock market due to consistent rate hikes. Biogen Inc. (BIBB) is one of the older global biotech... + más
Biogen to pay $900M to settle allegations of improper physician kickbacks | Fox Business
Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs | CNBC
Fox Business USA Business September 28, 2022
Dr. Stephen O'Brien, chief medical officer of Mediflix, shares how his streaming platform is trailblazing access to medical information for everyone. Shares of Biogen surged Wednesday's following news that its drug lecanemab showed promising signs of potentially... + más
Biogen shares rally as Alzheimer's drug results show promise | CBS News
Alzheimer's drug shows promise in early results of study | WPLG Local 10
About iurex | Privacy Policy | Disclaimer |